Bkca channel activator for treating muscular disorder
AssigneeCanbex Therapeutics Limited
InventorsDavid Selwood, David Baker
Life of this patent
Estimating the term…
Abstract
The present invention relates to BKCa activators for use in the treatment of a muscular disorder, or for controlling spasticity or tremors, for example, spasticity in MS.
Claims14
A method of treating a muscular disorder in a subject in need thereof, comprising administering to the subject a BKCa channel activator.
A method of treating or controlling spasticity or tremors in a subject in need thereof, comprising administering to the subject a BKCa channel activator.
10-12. (canceled)
A method of treating or controlling spasticity or tremors in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a BKCa channel activator selected from the following:
- TA1702 (Tanabe Seiyaku);
- or LDD175 (4-chloro-7-trifluoromethyl-10Hbenzo[4,5]furo[3,2-b]indole-1-carboxylic acid);
- or pharmaceutically acceptable salts, esters or hydrates thereof.
14-15. (canceled)
Dependencies are inferred from the claim text.